Cardiff Oncology (CRDF) 10-Q 9 Nov 17 2017 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2017	Oct. 31, 2017
Document and Entity Information
Entity Registrant Name	Trovagene, Inc.
Entity Central Index Key	1,213,037
Document Type	10-Q
Document Period End Date	Sep. 30, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		38,106,460
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q3

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 7,434,298	$ 13,915,094
Short-term investments	0	23,978,022
Accounts receivable	178,127	100,460
Prepaid expenses and other current assets	939,200	956,616
Total current assets	8,551,625	38,950,192
Property and equipment, net	3,126,969	3,826,915
Other assets	539,309	1,173,304
Total Assets	12,217,903	43,950,411
Current liabilities:
Accounts payable	675,499	1,130,536
Accrued expenses	2,620,250	4,021,365
Deferred rent	298,213	285,246
Current portion of long-term debt (in default)	1,488,041	2,360,109
Total current liabilities	5,082,003	7,797,256
Long-term debt, less current portion	0	14,176,359
Derivative financial instruments—warrants	2,037,712	834,940
Deferred rent, net of current portion	1,153,316	1,373,717
Total Liabilities	8,273,031	24,182,272
Commitments and contingencies (Note 9)
Stockholders’ equity
Preferred stock, $0.001 par value, 20,000,000 shares authorized; 60,600 shares outstanding at September 30, 2017 and December 31, 2016; designated as Series A Convertible Preferred Stock with liquidation preference of $606,000 at September 30, 2017 and December 31, 2016	60	60
Common stock, $0.0001 par value, 150,000,000 shares authorized; 38,105,251 and 30,696,791 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively	3,811	3,070
Additional paid-in capital	174,426,891	167,890,984
Accumulated other comprehensive loss	(15,194)	(10,773)
Accumulated deficit	(170,470,696)	(148,115,202)
Total stockholders’ equity	3,944,872	19,768,139
Total liabilities and stockholders’ equity	$ 12,217,903	$ 43,950,411

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Preferred stock, par value (in USD per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares outstanding	60,600	60,600
Series A Convertible Preferred Stock, liquidation preference (in dollars)	$ 606,000	$ 606,000
Common stock, par value (in USD per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	38,105,251	30,696,791
Common stock, shares outstanding	38,105,251	30,696,791

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Income Statement [Abstract]
Royalties	$ 58,779	$ 47,236	$ 169,415	$ 207,869
Diagnostic services	58,119	37,978	142,482	69,558
Clinical research services	6,431	3,900	8,481	35,573
Total revenues	123,329	89,114	320,378	313,000
Costs and expenses:
Cost of revenues	473,202	424,559	1,427,831	1,143,293
Research and development	1,414,706	3,937,398	6,676,251	11,221,876
Selling and marketing	419,927	2,940,862	2,442,931	9,127,450
General and administrative	3,659,587	2,710,782	9,915,359	9,183,761
Restructuring Charges	(46,472)	0	1,669,526	0
Total operating expenses	5,920,950	10,013,601	22,131,898	30,676,380
Loss from operations	(5,797,621)	(9,924,487)	(21,811,520)	(30,363,380)
Net interest expense	(16,473)	(354,993)	(877,741)	(967,522)
Gain from change in fair value of derivative financial instruments—warrants	1,528,669	88,208	2,012,747	674,834
Loss on extinguishment of debt	0	0	(1,655,825)	0
Other loss, net	(6,541)	0	(4,975)	0
Net loss	(4,291,966)	(10,191,272)	(22,337,314)	(30,656,068)
Preferred stock dividend	(6,060)	(6,060)	(18,180)	(18,180)
Net loss attributable to common stockholders	$ (4,298,026)	$ (10,197,332)	$ (22,355,494)	$ (30,674,248)
Net loss per common share - basic (in USD per share)	$ (0.12)	$ (0.34)	$ (0.68)	$ (1.02)
Net loss per common share - diluted (in USD per share)	$ (0.12)	$ (0.34)	$ (0.68)	$ (1.04)
Weighted-average shares outstanding — basic	36,465,672	30,339,774	32,826,306	30,018,841
Weighted-average shares outstanding — diluted	36,465,672	30,339,774	32,826,306	30,136,572

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Statement - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Statement of Comprehensive Income [Abstract]
Net loss	$ (4,291,966)	$ (10,191,272)	$ (22,337,314)	$ (30,656,068)
Other Comprehensive Income (Loss), Net of Tax [Abstract]
Foreign currency translation loss	(1,544)	(81)	(13,486)	(1,877)
Unrealized gain or reversal of previous losses on securities available-for-sale	0	(7,997)	9,065	(2,865)
Total other comprehensive income (loss)	(1,544)	(8,078)	(4,421)	(4,742)
Total comprehensive loss	(4,293,510)	(10,199,350)	(22,341,735)	(30,660,810)
Preferred stock dividend	6,060	6,060	18,180	18,180
Comprehensive loss attributable to common stockholders	$ (4,299,570)	$ (10,205,410)	$ (22,359,915)	$ (30,678,990)

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Operating activities
Net loss	$ (22,337,314)	$ (30,656,068)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on disposal of assets	28,199	0
Impairment loss	485,000	0
Depreciation and amortization	956,995	693,485
Stock based compensation expense	3,117,364	5,942,392
Loss on extinguishment of debt	1,655,825	0
Accretion of final fee premium	293,614	266,423
Amortization of discount on debt	113,780	105,710
Net realized loss on short-term investments	6,400	0
Amortization of premiums on short-term investments	9,230	61,719
Deferred rent	(207,435)	(133,378)
Interest income accrued on short-term investments	(90,330)	10,122
Change in fair value of derivative financial instruments—warrants	(2,012,747)	(674,834)
Changes in operating assets and liabilities:
Decrease in other assets	0	2,761
(Increase) decrease in accounts receivable	(77,667)	13,584
Decrease (increase) in prepaid expenses and other current assets	18,230	(157,051)
(Decrease) increase in accounts payable and accrued expenses	(1,908,796)	2,490,137
Net cash used in operating activities	(19,949,652)	(22,034,998)
Investing activities:
Capital expenditures, net	(136,251)	(797,781)
Proceeds from Sale and Maturity of Available-for-sale Securities	16,431,837	0
Payments for (Proceeds from) Short-term Investments	(8,804,604)	(24,451,611)
Proceeds from Sale of Available-for-sale Securities	16,434,553	0
Net cash provided by (used in) investing activities	23,925,535	(25,249,392)
Financing activities:
Proceeds from sales of common stock, net of expenses	6,634,803	2,293,857
Proceeds from exercise of options	0	366,966
Borrowings under equipment line of credit	0	792,251
Borrowings under long-term debt, net of costs	0	7,805,086
Payment upon debt extinguishment	(1,613,067)	0
Repayments of long-term debt	(15,000,000)	(8,896,166)
Repayments of equipment line of credit	(469,578)	0
Net cash (used in) provided by financing activities	(10,447,842)	2,361,994
Effect of exchange rate changes on cash and cash equivalents	(8,837)	(1,544)
Net change in cash and equivalents	(6,480,796)	(44,923,940)
Cash and cash equivalents—Beginning of period	13,915,094	67,493,047
Cash and cash equivalents—End of period	7,434,298	22,569,107
Supplementary disclosure of cash flow activity:
Cash paid for taxes	800	4,560
Cash paid for interest	650,331	806,228
Supplemental disclosure of non-cash investing and financing activities:
Preferred stock dividends accrued	18,180	18,180
Leasehold improvements paid for by lessor	$ 0	$ 1,860,000

Organization and Basis of Prese

Organization and Basis of Presentation	9 Months Ended
	Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Basis of Presentation	Organization and Basis of Presentation Business Organization and Overview Trovagene, Inc. (“Trovagene” or the “Company”) headquartered in San Diego, California, is a clinical-stage, precision medicine oncology therapeutics company. The Company’s primary focus is to develop oncology therapeutics for improved cancer care, optimizing drug development by leveraging its proprietary Precision Cancer Monitoring® (“PCM”) diagnostic technology in tumor genomics. Trovagene’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (“PLK1”) selective adenosine triphosphate (“ATP”) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and synergy in combination with more than ten different chemotherapeutics and targeted therapies, such as Zytiga® (abiraterone acetate), Beleodaq® (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade® (bortezomib) in Acute Myeloid Leukemia (“AML”), metastatic Castration-Resistant Prostate Cancer (“mCRPC”) and other liquid and solid tumor cancers. PCM-075 was developed to have high selectivity to PLK1, to be administered orally, and to have a relatively short drug half-life of approximately 24 hours compared to other PLK inhibitors. PCM-075 has completed a safety study in patients with advanced metastatic solid tumors with a phase 1b/2 clinical trial in patients with AML underway. Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements of Trovagene, which include all accounts of its wholly owned subsidiary, Trovagene, Srl, have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). All intercompany balances and transactions have been eliminated. The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with GAAP and the rules and regulations of the Securities and Exchange Commission (“SEC”) related to a quarterly report on Form 10-Q. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to those rules and regulations. The unaudited interim condensed consolidated financial statements reflect all adjustments consisting of normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the Company’s financial position and the results of its operations and cash flows for the periods presented. The unaudited condensed balance sheet at December 31, 2016 has been derived from the audited financial statements at that date but does not include all of the information and disclosures required by GAAP for annual financial statements. The operating results presented in these unaudited interim condensed consolidated financial statements are not necessarily indicative of the results that may be expected for any future periods. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto for the year ended December 31, 2016 included in the Company’s annual report on Form 10-K filed with the SEC on March 15, 2017. Liquidity Trovagene’s condensed consolidated financial statements as of September 30, 2017 have been prepared under the assumption that Trovagene will continue as a going concern, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty concerning the Company’s ability to continue as a going concern. However, the Company has incurred net losses since its inception and has negative operating cash flows. The Company also received a default letter from Silicon Valley Bank (“SVB”) regarding the Loan and Security Agreement entered in November 2015 which stated that events of default had occurred and SVB will decide in its sole discretion whether or not to exercise rights and remedies. Based on its current business plan and assumptions, the Company expects to continue to incur significant losses and require significant additional capital to further advance its clinical trial programs and support its other operations. Considering the Company’s current cash resources, including the net proceeds received from the offering of its equity securities in July 2017, management believes the Company’s existing resources will be sufficient to fund the Company’s planned operations into the first quarter of 2018. In addition, the Company has based its cash sufficiency estimates on its current business plan and its assumptions that may prove to be wrong. The Company could utilize its available capital resources sooner than it currently expects, and it could need additional funding to sustain its operations even sooner than currently anticipated. These circumstances raise substantial doubt about the Company’s ability to continue as a going concern. For the foreseeable future, the Company’s ability to continue its operations is dependent upon its ability to obtain additional capital. The Company cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that the Company can raise additional funds by issuing equity securities, the Company’s stockholders may experience significant dilution. Any debt financing, if available, may involve restrictive covenants that impact the Company’s ability to conduct its business. If the Company is unable to raise additional capital when required or on acceptable terms, it may have to significantly delay, scale back or discontinue the development and/or commercialization of one or more of its product candidates, all of which may have a material adverse impact on the Company’s operations. The Company may also be required to: • Seek collaborators for product candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise be available; and • Relinquish licenses or otherwise dispose of rights to technologies, product candidates or products that the Company would otherwise seek to develop or commercialize themselves, on unfavorable terms. The Company is evaluating the following options to raise additional capital, increase revenue, as well as reduce costs, in an effort to strengthen its liquidity position: • Raising capital through public and private equity offerings; • Adding capital through short-term and long-term borrowings; • Introducing operation and business development initiatives to bring in new revenue streams by leveraging capabilities within our CLIA lab, as well as monetizing our proprietary NextCollect™ DNA collection and preservation cup; • Reducing operating costs by identifying internal synergies; • Engaging in strategic partnerships; and • Taking actions to reduce or delay capital expenditures. On October 25, 2017, the Company filed a registration statement on Form S-1 with the SEC for a best efforts public offering of up to $17.5 million of common stock and warrants. The Company continually assesses any spending plans, including a review of its discretionary spending in connection with certain strategic contracts, to effectively and efficiently address its liquidity needs. NASDAQ Notice On September 5, 2017, the Company received a written notice from the NASDAQ Stock Market LLC (“NASDAQ”) that it was not in compliance with NASDAQ Listing Rule 5550(a)(2) for continued listing on the NASDAQ Capital Market, as the minimum bid price of the Company’s common stock had been below $1.00 per share for 30 consecutive business days. In accordance with NASDAQ Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until March 5, 2018, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company’s common stock must meet or exceed $1.00 per share for at least ten consecutive business days during this 180 calendar day period.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Short-Term Investments Short-term investments consisted of corporate debt securities, U.S. treasury securities, and commercial paper. The Company classified its short-term investments as available-for-sale, as the sale of such securities may be required prior to maturity to execute management strategies. Investments classified as available-for-sale are carried at fair value, with the unrealized gains and losses reported as a component of consolidated accumulated other comprehensive income (loss) in stockholders’ equity until realized. Realized gains and losses from the sale of available-for-sale securities were determined on a specific identification basis. A decline in the market value of any available-for-sale security below cost that is determined to be other than temporary will result in an impairment charge to earnings and a new cost basis for the security is established. No such impairment charges were recorded for any period presented. Premiums and discounts were amortized or accreted over the life of the related security as an adjustment to yield using the straight-line method and included in interest income. Interest income was recognized when earned. Realized gains and losses on investments in securities were included in other income (loss) within the consolidated statements of operations. As of September 30, 2017 , all of the short-term investments have been sold to satisfy the Company’s outstanding obligations under the Loan and Security Agreement dated as of June 30, 2014 upon demanding repayment by the lenders. As a result, the Company recognized net realized loss of approximately $6,400 for the nine months ended September 30, 2017 . Revenue Recognition Revenue is recognized when persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and collection is reasonably assured. Milestone, Royalty and License Revenues The Company licenses and sublicenses its patent rights to healthcare companies, medical laboratories and biotechnology partners. These agreements may involve multiple elements such as license fees, royalties and milestone payments. Revenue is recognized when the criteria described above have been met as well as the following: • Up-front nonrefundable license fees pursuant to agreements under which the Company has no continuing performance obligations are recognized as revenues on the effective date of the agreement and when collection is reasonably assured. • Minimum royalties are recognized as earned, and royalties are earned based on the licensee’s use. The Company is unable to predict licensee’s sales and thus revenue is recognized upon receipt of notification from licensee and payment when collection is assured. Notification is generally one quarter in arrears. • Milestone payments are recognized when both the milestone is achieved and the related payment is received. Diagnostic Service Revenues Revenue for clinical laboratory tests may come from several sources, including commercial third-party payors, such as insurance companies and health maintenance organizations, government payors, such as Medicare and Medicaid in the United States, patient self-pay and, in some cases, from hospitals or referring laboratories who, in turn, might bill third-party payors for testing. The Company is recognizing diagnostic service revenue on the cash collection basis until such time as it is able to properly estimate collections on third party reimbursements. Clinical Research Services Revenue Revenue from clinical research services consists of revenue from the sale of urine and blood collection supplies and tests performed under agreements with our clinical research and business development partners. Revenue was recognized when supplies and/or test results were delivered. Cost of Revenue Cost of revenue represents the cost of materials, personnel costs and costs associated with processing specimens including pathological review, quality control analyses, and delivery charges necessary to render an individualized test result. Costs associated with performing tests are recorded as the tests are processed. However, the revenue on diagnostic services is recognized on a cash collection basis resulting in costs incurred before the collection of related revenue. Derivative Financial Instruments—Warrants The Company has issued common stock warrants in connection with the execution of certain equity financings. Such warrants are classified as derivative liabilities under the provisions of Financial Accounting Standards Board (“FASB”) ASC 815 Derivatives and Hedging (“ASC 815”) or ASC 480 Distinguishing Liabilities from Equity (“ASC 480”) are recorded at their fair market value as of each reporting period. Such warrants do not meet the exemption that a contract should not be considered a derivative instrument if it is (1) indexed to its own stock and (2) classified in stockholders’ equity. The warrants within the scope of ASC 480 contain a feature that could require the transfer of cash in the event a change of control occurs without an authorization of our Board of Directors, and therefore classified as a liability. Changes in fair value of derivative liabilities are recorded in the consolidated statement of operations under the caption “Change in fair value of derivative instruments.” The fair value of warrants is determined using the Black-Scholes option-pricing model using assumptions regarding the volatility of Trovagene’s common stock price, the remaining life of the warrants, and the risk-free interest rates at each period end. The Company thus uses model-derived valuations where inputs are observable in active markets to determine the fair value and accordingly classifies such warrants in Level 3 per FASB ASC Topic 820, Fair Value Measurements (“ASC 820”). At September 30, 2017 and December 31, 2016 , the fair value of these warrants was $2,037,712 and $834,940 , respectively, and was recorded as a liability under the caption “derivative financial instruments — warrants” on the consolidated balance sheets. Net Loss Per Share Basic and diluted net loss per share is presented in conformity with ASC Topic 260, Earnings per Share , for all periods presented. In accordance with this guidance, basic net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. Preferred dividends are included in income available to common stockholders in the computation of basic and diluted earnings per share. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common share equivalents outstanding for the period. Common share equivalents are only included when their effect is dilutive. The following table sets forth the computation of basic and diluted earnings per share: Three Months Nine Months 2017 2016 2017 2016 Numerator: Net loss attributable to common shareholders $ (4,298,026 ) $ (10,197,332 ) $ (22,355,494 ) $ (30,674,248 ) Adjustment for gain from change in fair value of derivative financial instruments — warrants — — — (533,750 ) Net loss used for diluted loss per share $ (4,298,026 ) $ (10,197,332 ) $ (22,355,494 ) $ (31,207,998 ) Denominator for basic and diluted net loss per share: Weighted-average shares used to compute basic loss per share 36,465,672 30,339,774 32,826,306 30,018,841 Adjustments to reflect assumed exercise of warrants — — — 117,731 Weighted-average shares used to compute diluted net loss per share 36,465,672 30,339,774 32,826,306 30,136,572 Net loss per share attributable to common stockholders: Basic $ (0.12 ) $ (0.34 ) $ (0.68 ) $ (1.02 ) Diluted $ (0.12 ) $ (0.34 ) $ (0.68 ) $ (1.04 ) The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their effect was anti-dilutive: September 30, 2017 2016 Options to purchase Common Stock 4,257,031 6,051,186 Warrants to purchase Common Stock 8,972,503 4,546,939 Restricted Stock Units 1,277,302 392,000 Series A Convertible Preferred Stock 63,125 63,125 14,569,961 11,053,250 License Fees The Company expenses amounts paid to acquire licenses associated with products under development when the ultimate recoverability of the amounts paid is uncertain and the technology has no alternative future use when acquired. Acquisitions of technology licenses are charged to expense or capitalized based upon management’s assessment regarding the ultimate recoverability of the amounts paid and the potential for alternative future use. The Company has determined that technological feasibility for its product candidates is reached when the requisite regulatory approvals are obtained to make the product available for sale. Restructuring Restructuring costs are included in loss from operations in the condensed consolidated statements of operations. The Company has accounted for these costs in accordance with ASC Topic 420, Exit or Disposal Cost Obligations . One-time termination benefits are recorded at the time they are communicated to the affected employees. In March 2017, the Company announced a restructuring plan which is expected to be completed in the last quarter of 2017. See Note 10 to the condensed consolidated financial statements for further information. Recent Accounting Pronouncements In August 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-15, Classification of Certain Cash Receipts and Cash Payments (“ASU 2016-15”), which includes amendments that clarify how certain cash receipts and cash payments are presented in the statement of cash flows. ASU 2016-15 also provides guidance clarifying when an entity should separate cash receipts and cash payments and classify them into more than one class of cash flows. The new amendments and guidance are effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted provided that all amendments are adopted in the same period. The Company is currently evaluating the impact of adoption of ASU 2016-15 on its consolidated statements of cash flows. In February 2016, the FASB issued ASU 2016-02, Leases . The new standard establishes a right-of-use (“ROU”) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for most leases. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The new standard will impact the Company’s accounting for its office leases and the Company is currently evaluating the impact of the new standard on its consolidated financial statements. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”). The new standard is based on the principle that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Since its initial release, the FASB has issued several amendments to the standard, which include clarification of accounting guidance related to identification of performance obligations, intellectual property licenses, and principle versus agent considerations. ASU 2014-09 and all subsequent amendments (collectively, the “new standards”) will be effective for the Company beginning in the first quarter of fiscal year 2018 and may be applied using either the full retrospective method, in which case the new standards would be applied to each prior reporting period presented, or the modified retrospective method, in which case the cumulative effect of applying the new standards would be recognized at the date of initial application. The Company has reviewed its revenue streams to identify potential differences in accounting as a result of the new standards. Currently, the Company does not have any significant contracts with customers given its stage of development. The Company has derived its revenues primarily from a limited number of royalty, license and diagnostic service agreements. The consideration the Company is eligible to receive under these agreements includes upfront license payments, milestone payments and royalties. Each of these agreements has unique terms that are being evaluated separately under the new standards. The new standards differ from the current accounting standard in many respects, such as in the accounting for variable consideration, including milestone payments. For example, the Company currently recognizes milestone revenue using the milestone method specified in ASC 605-28, which generally results in recognition of milestone revenue in the period that the milestone event is achieved. However, under the new standards, it is possible to start to recognize milestone revenue before the milestone is achieved if management determines with a high degree of certainty that amounts recorded as revenues will not have to be reversed when the uncertainty associated with the variable consideration is subsequently resolved. The Company is also continuing to assess the potential impact that the new standards may have with respect to its diagnostic service revenue which is currently recognized on a cash collection basis. Under the new standards, the Company may recognize diagnostic service revenue upon delivery of test results if management determines with a high degree of certainty that amounts recorded as revenues will not have to be reversed when the uncertainty associated with the variable consideration is subsequently resolved. The Company is continuing to assess the impact the new standards will have on its financial statements and expects to complete the assessment on or before the year-end 2017. The Company does not expect a significant change in the timing and recognition of its revenue upon adoption of the new standards. The Company expects to adopt the new standards using the modified retrospective method with an adjustment, if any, to beginning retained earnings for the cumulative effect of the change.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The following table presents the Company’s assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of September 30, 2017 and December 31, 2016 : Fair Value Measurements at Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets: Money market fund (1) $ 6,510,214 $ — $ — $ 6,510,214 Total Assets $ 6,510,214 $ — $ — $ 6,510,214 Liabilities: Derivative financial instruments — warrants $ — $ — $ 2,037,712 $ 2,037,712 Total Liabilities $ — $ — 2,037,712 $ 2,037,712 Fair Value Measurements at Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets: Money market fund (1) $ 12,095,620 $ — $ — $ 12,095,620 Corporate debt securities (2) — 14,160,686 — 14,160,686 Commercial paper (3) — 2,393,948 — 2,393,948 U.S. treasury securities (2) — 8,621,892 — 8,621,892 Total Assets $ 12,095,620 $ 25,176,526 $ — $ 37,272,146 Liabilities: Derivative financial instruments — warrants $ — $ — $ 834,940 $ 834,940 Total Liabilities $ — $ — $ 834,940 $ 834,940 (1) Included as a component of cash and cash equivalents on the accompanying condensed consolidated balance sheets. (2) Included in short-term investments on the accompanying condensed consolidated balance sheets. (3) $0 and $1,198,504 of commercial paper was included as a component of cash and cash equivalents at September 30, 2017 and December 31, 2016 , respectively, and the remaining amount was included in short-term investments on the accompanying consolidated balance sheets. The following table sets forth a summary of changes in the fair value of the Company’s Level 3 liabilities for the nine months ended September 30, 2017 : Description Balance at Issuance of Derivative Financial Instruments Realized Gain Balance at Derivative financial instruments — warrants $ 834,940 3,215,519 $ (2,012,747 ) $ 2,037,712 The realized gains or losses on the derivative financial instruments—warrants are recorded as a change in fair value of derivative financial instruments—warrants in the Company’s consolidated statement of operations. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, the Company reviews the assets and liabilities that are subject to ASC Topic 815-40. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments that trade infrequently and therefore have little or no price transparency are classified as Level 3.

Short-Term Investments

Short-Term Investments	9 Months Ended
	Sep. 30, 2017
Investments, Debt and Equity Securities [Abstract]
Short-Term Investments	Short-Term Investments As of September 30, 2017 , all short-term investments have been sold to satisfy the Company’s outstanding obligations under the Loan and Security Agreement dated as of June 30, 2014 upon demanding repayment by the lenders. The following table sets forth the composition of short-term investments as of December 31, 2016 . December 31, 2016 Unrealized Maturity in Years Cost Gains Losses Fair Value Corporate debt securities Less than 1 year $ 14,165,915 $ 44 $ (5,273 ) $ 14,160,686 Commercial paper Less than 1 year 1,195,444 — — 1,195,444 U.S. treasury securities Less than 1 year 8,625,728 330 (4,166 ) 8,621,892 Total Investment $ 23,987,087 $ 374 $ (9,439 ) $ 23,978,022

Property and Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2017
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment Property and equipment consist of the following: As of September 30, As of December 31, Furniture and office equipment $ 1,076,709 $ 1,144,741 Leasehold improvements 1,994,514 1,994,514 Laboratory equipment 2,584,363 2,449,645 5,655,586 5,588,900 Less—accumulated depreciation and amortization (2,528,617 ) (1,761,985 ) Property and equipment, net $ 3,126,969 $ 3,826,915

Debt

Debt	9 Months Ended
	Sep. 30, 2017
Debt Disclosure [Abstract]
Debt	Debt Equipment Line of Credit In November 2015, the Company entered into a Loan and Security Agreement (“Equipment Line of Credit”) with SVB that provided for cash borrowings for equipment (“Equipment Advances”) of up to $2.0 million , secured by the equipment financed. Under the terms of the agreement, interest is equal to 1.25% above the Prime Rate. At September 30, 2017 , the interest rate was 5.50% . Interest only payments are due on borrowings through November 30, 2016, with both interest and principal payments commencing in December 2016. All unpaid principal and interest on each Equipment Advance will be due on November 1, 2019. The Company has an obligation to make a final payment equal to 7% of total amounts borrowed at the loan maturity date. The Company is also subject to certain affirmative and negative covenants under the Equipment Line of Credit. On June 20, 2017, the Company received a Notice of Event of Default (“Default Letter”) from SVB which stated that Events of Default had occurred and SVB will decide in its sole discretion whether or not to exercise rights and remedies. Pursuant to the Default Letter, the Company has classified the entire balance of $1,488,041 as a current liability as of September 30, 2017 and also started recording accrued interest at a default rate. The Company recorded $209,082 in interest expense related to the Equipment Line of Credit during the nine months ended September 30, 2017 . The Company is currently working with lender for resolution. Loan and Security Agreement In June 2014, the Company entered into a $15,000,000 Loan and Security Agreement (“Agreement”) under which the lenders provided the Company a term loan. On July 20, 2016, the Company signed the 5th Amendment to Loan and Security Agreement to refinance its existing term loan. Under the Amendment, interest is equal to 3.75% plus the Wall Street Journal Prime Rate, subject to a floor of 7.25% . The Company is required to make interest only payments on the outstanding amount of the loan on a monthly basis through September 1, 2017, after which equal monthly payments of principal and interest are due until the loan maturity date of February 1, 2020. On June 1, 2017, the Company received a Notice of Event of Default from the lenders which stated that Events of Default had occurred and all of the obligation under the Agreement were immediately due and payable. On June 6, 2017, the lenders took the total pay-off amount of $16,668,583 for the principal, interest, final payment, and other amounts out of the Company’s bank accounts which satisfied all of the Company’s outstanding obligations under the Agreement. Accordingly, the Agreement was terminated in June 2017. Upon termination of the Agreement, the prepayment fee of $450,000 , unamortized debt discount of $400,562 and unamortized final fee of $738,196 were recorded as loss on debt extinguishment. The Company recorded total interest expense of $ 801,173 related to the Agreement during the nine months ended September 30, 2017 .

Derivative Financial Instrument

Derivative Financial Instruments - Warrants	9 Months Ended
	Sep. 30, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments - Warrants	Derivative Financial Instruments — Warrants Based upon the Company’s analysis of the criteria contained in ASC Topic 815-40, Contracts in Entity’s Own Equity (“ASC 815-40”) or ASC Topic 480-10, Distinguishing Liabilities from Equity (“ASC 480-10”), Trovagene determined that certain warrants issued in connection with the execution of certain equity financings must be recorded as derivative liabilities. In accordance with ASC 815-40 and ASC 480-10, the warrants are also being re-measured at each balance sheet date based on estimated fair value, and any resultant change in fair value is being recorded in the Company’s condensed consolidated statements of operations. The Company estimates the fair value of these warrants using the Black-Scholes option pricing model. The range of assumptions used to determine the fair value of the warrants valued using the Black-Scholes option pricing model during the periods indicated was: Nine Months Ended September 30, 2017 2016 Estimated fair value of Trovagene common stock 0.73-1.26 4.49-4.65 Expected warrant term 1.3-5.5 years 2.3-2.8 years Risk-free interest rate 1.27-1.95% 0.71-0.87% Expected volatility 86-109% 82-89% Dividend yield 0 % 0 % Expected volatility is based on historical volatility of Trovagene’s common stock. The warrants have a transferability provision and based on guidance provided in Staff Accounting Bulletin (“SAB”) No. 107, Share-Based Payment (“SAB No. 107”) , for instruments issued with such a provision, Trovagene used the remaining contractual term as the expected term of the warrants. The risk free rate is based on the U.S. Treasury security rates consistent with the expected remaining term of the warrants at each balance sheet date. The following table sets forth the components of changes in the Company’s derivative financial instruments — warrants liability balance, valued using the Black-Scholes option pricing method, for the periods indicated. Date Description Number of Warrants Derivative Instrument Liability December 31, 2016 Balance of derivative financial instruments — warrants liability 967,295 $ 834,940 Issuance of derivative financial instruments 4,643,626 3,215,519 Change in fair value of derivative financial instruments — warrants during the period recognized as a gain in the condensed consolidated statements of operations — (2,012,747 ) September 30, 2017 Balance of derivative financial instruments — warrants liability 5,610,921 $ 2,037,712

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2017
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Stockholders’ Equity Common Stock During the nine months ended September 30, 2017 , the Company issued a total of 7,408,460 shares of Common Stock. The Company received gross proceeds of approximately $7.1 million from the sale of 6,191,500 shares of its common stock and 4,643,626 share of warrants through registered direct offering and private placement in July 2017. The Company received gross proceeds of approximately $0.1 million from the sale of 102,081 shares of its common stock at a weighted average price of $1.08 under the agreement with Cantor Fitzgerald & Co. (“Agent”). In addition, 369,487 shares were issued upon vesting of restricted stock units (“RSU”), and 745,392 shares were issued upon vesting of restricted stock awards (“RSA”). Stock Options Stock-based compensation expense related to Trovagene equity awards have been recognized in operating results as follow: Three Months Ended Nine Months Ended 2017 2016 2017 2016 Included in research and development expense $ 219,480 $ 872,792 $ 798,143 $ 1,862,069 Included in cost of revenue 15,633 42,639 56,998 99,164 Included in selling and marketing expense 118,434 476,865 550,317 1,493,744 Included in general and administrative expense 1,067,633 437,075 1,837,128 2,487,415 Benefit from restructuring — — (125,222 ) — Total stock-based compensation expense $ 1,421,180 $ 1,829,371 $ 3,117,364 $ 5,942,392 The unrecognized compensation cost related to non-vested stock options outstanding at September 30, 2017 and 2016 , net of expected forfeitures, was $3,271,046 and $10,416,565 , respectively, which is expected to be recognized over a weighted-average remaining vesting period of 2.2 and 3.0 years , respectively. The weighted-average remaining contractual term of outstanding options as of September 30, 2017 was approximately 7.2 years . The total fair value of stock options vested during the nine months ended September 30, 2017 and 2016 was $3,378,243 and $5,416,168 , respectively. The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions during the following periods indicated: Nine Months Ended 2017 2016 Risk-free interest rate 1.82 % 1.48 % Dividend yield 0 % 0 % Expected volatility 87 % 103 % Expected term 5.2 years 5.5 years A summary of stock option activity and changes in stock options outstanding is presented below: Total Options Weighted-Average Exercise Price Per Share Intrinsic Value Balance outstanding, December 31, 2016 5,528,628 $ 5.49 $ — Granted 823,106 $ 0.84 Canceled / Forfeited (2,077,246 ) $ 6.24 Expired (17,457 ) $ 4.74 Balance outstanding, September 30, 2017 4,257,031 $ 4.23 $ 381 Exercisable at September 30, 2017 2,492,242 $ 4.79 $ — On June 13, 2017, the number of authorized shares in the Trovagene 2014 Equity Incentive Plan (“2014 EIP”) was increased from 7,500,000 to 9,500,000 . As of September 30, 2017 there were 3,670,232 shares available for issuance under the 2014 EIP. Restricted Stock Units The weighted-average grant date fair value of the RSU was $1.59 and $4.06 per share during the nine months ended September 30, 2017 and 2016 , respectively. A summary of the RSU activity is presented below: Number of Shares Weighted-Average Grant Date Fair Value Per Share Intrinsic Value Non-vested RSU outstanding, December 31, 2016 272,000 $ 3.99 $ 571,200 Granted 2,249,242 $ 1.59 Vested (369,487 ) $ 3.48 $ 645,775 Forfeited (874,453 ) $ 1.75 Non-vested RSU outstanding, September 30, 2017 1,277,302 $ 1.44 $ 932,430 At September 30, 2017 , total unrecognized compensation cost related to non-vested RSU was $1,011,494 , which is expected to be recognized over a weighted-average period of 2.5 years . The total fair value of vested RSU during the nine months ended September 30, 2017 was $1,285,578 . Restricted Stock Awards During the nine months ended September 30, 2017 , a total of 745,392 shares of RSA were granted, all of which were vested immediately. The total fair value of vested RSA during the nine months ended September 30, 2017 was $596,314 . The weighted-average grant date fair value of the RSA was $0.80 per share during the nine months ended September 30, 2017 . There were no such awards granted during the nine months ended September 30, 2016 . Warrants A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications is presented below: Total Warrants Weighted-Average Exercise Price Per Share Weighted-Average Remaining Contractual Term Balance outstanding, December 31, 2016 5,505,901 $ 3.83 1.6 Granted 4,643,626 $ 1.41 Expired (1,177,024 ) $ 5.32 Balance outstanding, September 30, 2017 8,972,503 $ 2.38 3.3

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Executive and Consulting Agreements The Company has longer-term contractual commitments with various consultants and employees. Certain employment agreements provide for severance payments. Lease Agreements The Company leases approximately 26,100 square feet of office and laboratory space at a monthly rental rate of approximately $68,000 . The lease will expire on December 31, 2021. The Company currently subleases certain office space and records the rental receipt under the subleases as a reduction of its rent expense. The Company also leased certain lab and office space in Torino, Italy, of approximately 2,300 square feet, at a monthly rental rate of approximately $3,100 through the end of September 2017. Research and Development and Clinical Trial Agreements In March 2017, the Company entered into a license agreement with Nerviano which granted the Company development and commercialization rights to NMS-1286937, which Trovagene refers to as PCM-075. PCM-075 is an oral, investigative drug and a highly-selective adenosine triphosphate competitive inhibitor of the serine/threonine PLK 1. The Company plans to develop PCM-075 initially in patients with AML. Upon execution of the agreement, the Company paid $2.0 million in license fees which were expensed to research and development costs during the nine months ended September 30, 2017 . The Company is committed to pay $1.0 million for future services provided by Nerviano, such as the costs to manufacture drug product, no later than June 30, 2019. Terms of the agreement also provide for the Company to pay royalties based on certain development and sales milestones. The Company has entered into a variety of clinical trial and collaboration agreements relating to its drug development efforts. Included in research and development expense, the Company has recorded approximately $291,000 for the nine months ended September 30, 2017 relating to services provided in connection with these agreements. The Company is a party to various agreements under which it licenses technology on an exclusive basis in the field of human diagnostics. License fees are generally calculated as a percentage of product revenues, with rates that vary by agreement. To date, payments have not been material. Litigation Trovagene does not believe that the Company has legal liabilities that are probable or reasonably possible that require either accrual or disclosure, except for the following: On March 28, 2016 the Company filed a complaint in the Superior Court of the State of California for the County of San Diego against the Company’s former CEO and CFO, for, among other things, breach of fiduciary duty for failing to present a lucrative corporate opportunity to the Company concerning promising new therapeutics in the field of precision medicine and instead taking that opportunity for their own personal benefit (the “Complaint”). The Complaint asks that these two former executives be required to turn over their interests in these new therapeutics to the Company. The former CEO and CFO filed a cross complaint in the Superior Court of the State of California for the County of San Diego against the Company on May 23, 2016 for, among other things, breach of contract (the “Cross Complaint”, and together with the Complaint, collectively, the “Litigation”). On July 28, 2017, the parties settled the Litigation. The settlement involved mutual releases by all parties involved. The net cost to Trovagene in connection with the settlement is approximately $2.1 million . Of that amount, $975,000 was the net amount paid directly to the former CEO and CFO. From time to time, the Company may become involved in various lawsuits and legal proceedings that arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in matters may arise from time to time that may harm the Company’s business. As of the date of this report, management believes that there are no claims against the Company, which it believes will result in a material adverse effect on the Company’s business or financial condition. Public Offering and Controlled Equity Offering On March 15, 2017, the Company filed a Form 424B5 to amend and supplement the information in the Company’s registration statement and prospectus, dated June 13, 2016, to offer and sell additional shares of the Company’s common stock having an aggregate offering price up to $20,698,357 . The Company entered into an agreement with Cantor Fitzgerald & Co. (“Agent”) on January 25, 2013 to issue and sell up to $30,000,000 of shares of common stock through the Agent. As payment for its services, the Agent is entitled to a commission on gross proceeds of up to 3% . Gross proceeds of approximately $110,000 have been raised in 2017.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2017
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions In March 2016, the Company engaged Rutan & Tucker, LLP, a law firm to represent Trovagene, Inc. with respect to various lawsuits. One of the partners from Rutan & Tucker, LLP, is the son of the Company’s Chairman of the Board. The fees for legal services are based on the hourly rates of the individuals performing the legal services. During the nine months ended September 30, 2017 and 2016 , the Company has incurred approximately $763,075 and $377,464 of legal expenses, net of insurance reimbursements, for services performed by Rutan & Tucker, LLP, respectively.

Restructuring Charges

Restructuring Charges	9 Months Ended
	Sep. 30, 2017
Restructuring and Related Activities [Abstract]
Restructuring and Related Activities Disclosure [Text Block]	Restructuring Charges On March 15, 2017, in connection with the addition of precision medicine therapeutics to its business, the Company announced a restructuring plan (the “Restructuring”) which included a reduction in force. The Restructuring is expected to be completed in the last quarter of 2017. The Company estimates that it will incur approximately $2.0 million in charges related to this Restructuring. During the nine months ended September 30, 2017 , the Company incurred approximately $1.7 million in restructuring charges which included approximately $1.2 million of personnel termination costs and an approximately $0.5 million charge related to impairment of capitalized license fees. As of September 30, 2017 , approximately $0.4 million of these restructuring costs were included in accrued liabilities in the condensed consolidated balance sheet.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2017
Subsequent Events [Abstract]
Subsequent Events	Subsequent Event On October 25, 2017, the Company filed a registration statement on Form S-1 with the SEC for a best efforts public offering of up to $17.5 million of common stock and warrants. H.C. Wainwright & Co. is acting as placement agent.

Summary of Significant Accoun19

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Short-Term Investment	Short-Term Investments Short-term investments consisted of corporate debt securities, U.S. treasury securities, and commercial paper. The Company classified its short-term investments as available-for-sale, as the sale of such securities may be required prior to maturity to execute management strategies. Investments classified as available-for-sale are carried at fair value, with the unrealized gains and losses reported as a component of consolidated accumulated other comprehensive income (loss) in stockholders’ equity until realized. Realized gains and losses from the sale of available-for-sale securities were determined on a specific identification basis. A decline in the market value of any available-for-sale security below cost that is determined to be other than temporary will result in an impairment charge to earnings and a new cost basis for the security is established. No such impairment charges were recorded for any period presented. Premiums and discounts were amortized or accreted over the life of the related security as an adjustment to yield using the straight-line method and included in interest income. Interest income was recognized when earned. Realized gains and losses on investments in securities were included in other income (loss) within the consolidated statements of operations.
Revenue Recognition	Revenue Recognition Revenue is recognized when persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and collection is reasonably assured. Milestone, Royalty and License Revenues The Company licenses and sublicenses its patent rights to healthcare companies, medical laboratories and biotechnology partners. These agreements may involve multiple elements such as license fees, royalties and milestone payments. Revenue is recognized when the criteria described above have been met as well as the following: • Up-front nonrefundable license fees pursuant to agreements under which the Company has no continuing performance obligations are recognized as revenues on the effective date of the agreement and when collection is reasonably assured. • Minimum royalties are recognized as earned, and royalties are earned based on the licensee’s use. The Company is unable to predict licensee’s sales and thus revenue is recognized upon receipt of notification from licensee and payment when collection is assured. Notification is generally one quarter in arrears. • Milestone payments are recognized when both the milestone is achieved and the related payment is received. Diagnostic Service Revenues Revenue for clinical laboratory tests may come from several sources, including commercial third-party payors, such as insurance companies and health maintenance organizations, government payors, such as Medicare and Medicaid in the United States, patient self-pay and, in some cases, from hospitals or referring laboratories who, in turn, might bill third-party payors for testing. The Company is recognizing diagnostic service revenue on the cash collection basis until such time as it is able to properly estimate collections on third party reimbursements. Clinical Research Services Revenue Revenue from clinical research services consists of revenue from the sale of urine and blood collection supplies and tests performed under agreements with our clinical research and business development partners. Revenue was recognized when supplies and/or test results were delivered.
Cost of Revenue	Cost of Revenue Cost of revenue represents the cost of materials, personnel costs and costs associated with processing specimens including pathological review, quality control analyses, and delivery charges necessary to render an individualized test result. Costs associated with performing tests are recorded as the tests are processed. However, the revenue on diagnostic services is recognized on a cash collection basis resulting in costs incurred before the collection of related revenue.
Derivative Financial Instruments-Warrants	Derivative Financial Instruments—Warrants The Company has issued common stock warrants in connection with the execution of certain equity financings. Such warrants are classified as derivative liabilities under the provisions of Financial Accounting Standards Board (“FASB”) ASC 815 Derivatives and Hedging (“ASC 815”) or ASC 480 Distinguishing Liabilities from Equity (“ASC 480”) are recorded at their fair market value as of each reporting period. Such warrants do not meet the exemption that a contract should not be considered a derivative instrument if it is (1) indexed to its own stock and (2) classified in stockholders’ equity. The warrants within the scope of ASC 480 contain a feature that could require the transfer of cash in the event a change of control occurs without an authorization of our Board of Directors, and therefore classified as a liability. Changes in fair value of derivative liabilities are recorded in the consolidated statement of operations under the caption “Change in fair value of derivative instruments.” The fair value of warrants is determined using the Black-Scholes option-pricing model using assumptions regarding the volatility of Trovagene’s common stock price, the remaining life of the warrants, and the risk-free interest rates at each period end. The Company thus uses model-derived valuations where inputs are observable in active markets to determine the fair value and accordingly classifies such warrants in Level 3 per FASB ASC Topic 820, Fair Value Measurements (“ASC 820”).
Net Loss Per Share	Net Loss Per Share Basic and diluted net loss per share is presented in conformity with ASC Topic 260, Earnings per Share , for all periods presented. In accordance with this guidance, basic net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. Preferred dividends are included in income available to common stockholders in the computation of basic and diluted earnings per share. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common share equivalents outstanding for the period. Common share equivalents are only included when their effect is dilutive.
License Fees	License Fees The Company expenses amounts paid to acquire licenses associated with products under development when the ultimate recoverability of the amounts paid is uncertain and the technology has no alternative future use when acquired. Acquisitions of technology licenses are charged to expense or capitalized based upon management’s assessment regarding the ultimate recoverability of the amounts paid and the potential for alternative future use. The Company has determined that technological feasibility for its product candidates is reached when the requisite regulatory approvals are obtained to make the product available for sale.
Restructuring	Restructuring Restructuring costs are included in loss from operations in the condensed consolidated statements of operations. The Company has accounted for these costs in accordance with ASC Topic 420, Exit or Disposal Cost Obligations . One-time termination benefits are recorded at the time they are communicated to the affected employees. In March 2017, the Company announced a restructuring plan which is expected to be completed in the last quarter of 2017. See Note 10 to the condensed consolidated financial statements for further information.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In August 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-15, Classification of Certain Cash Receipts and Cash Payments (“ASU 2016-15”), which includes amendments that clarify how certain cash receipts and cash payments are presented in the statement of cash flows. ASU 2016-15 also provides guidance clarifying when an entity should separate cash receipts and cash payments and classify them into more than one class of cash flows. The new amendments and guidance are effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted provided that all amendments are adopted in the same period. The Company is currently evaluating the impact of adoption of ASU 2016-15 on its consolidated statements of cash flows. In February 2016, the FASB issued ASU 2016-02, Leases . The new standard establishes a right-of-use (“ROU”) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for most leases. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The new standard will impact the Company’s accounting for its office leases and the Company is currently evaluating the impact of the new standard on its consolidated financial statements. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”). The new standard is based on the principle that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Since its initial release, the FASB has issued several amendments to the standard, which include clarification of accounting guidance related to identification of performance obligations, intellectual property licenses, and principle versus agent considerations. ASU 2014-09 and all subsequent amendments (collectively, the “new standards”) will be effective for the Company beginning in the first quarter of fiscal year 2018 and may be applied using either the full retrospective method, in which case the new standards would be applied to each prior reporting period presented, or the modified retrospective method, in which case the cumulative effect of applying the new standards would be recognized at the date of initial application. The Company has reviewed its revenue streams to identify potential differences in accounting as a result of the new standards. Currently, the Company does not have any significant contracts with customers given its stage of development. The Company has derived its revenues primarily from a limited number of royalty, license and diagnostic service agreements. The consideration the Company is eligible to receive under these agreements includes upfront license payments, milestone payments and royalties. Each of these agreements has unique terms that are being evaluated separately under the new standards. The new standards differ from the current accounting standard in many respects, such as in the accounting for variable consideration, including milestone payments. For example, the Company currently recognizes milestone revenue using the milestone method specified in ASC 605-28, which generally results in recognition of milestone revenue in the period that the milestone event is achieved. However, under the new standards, it is possible to start to recognize milestone revenue before the milestone is achieved if management determines with a high degree of certainty that amounts recorded as revenues will not have to be reversed when the uncertainty associated with the variable consideration is subsequently resolved. The Company is also continuing to assess the potential impact that the new standards may have with respect to its diagnostic service revenue which is currently recognized on a cash collection basis. Under the new standards, the Company may recognize diagnostic service revenue upon delivery of test results if management determines with a high degree of certainty that amounts recorded as revenues will not have to be reversed when the uncertainty associated with the variable consideration is subsequently resolved. The Company is continuing to assess the impact the new standards will have on its financial statements and expects to complete the assessment on or before the year-end 2017. The Company does not expect a significant change in the timing and recognition of its revenue upon adoption of the new standards. The Company expects to adopt the new standards using the modified retrospective method with an adjustment, if any, to beginning retained earnings for the cumulative effect of the change.

Summary of Significant Accoun20

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Schedule of Computation of Basic and Diluted Earnings per Share	The following table sets forth the computation of basic and diluted earnings per share: Three Months Nine Months 2017 2016 2017 2016 Numerator: Net loss attributable to common shareholders $ (4,298,026 ) $ (10,197,332 ) $ (22,355,494 ) $ (30,674,248 ) Adjustment for gain from change in fair value of derivative financial instruments — warrants — — — (533,750 ) Net loss used for diluted loss per share $ (4,298,026 ) $ (10,197,332 ) $ (22,355,494 ) $ (31,207,998 ) Denominator for basic and diluted net loss per share: Weighted-average shares used to compute basic loss per share 36,465,672 30,339,774 32,826,306 30,018,841 Adjustments to reflect assumed exercise of warrants — — — 117,731 Weighted-average shares used to compute diluted net loss per share 36,465,672 30,339,774 32,826,306 30,136,572 Net loss per share attributable to common stockholders: Basic $ (0.12 ) $ (0.34 ) $ (0.68 ) $ (1.02 ) Diluted $ (0.12 ) $ (0.34 ) $ (0.68 ) $ (1.04 )
Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Net Loss per Share	The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their effect was anti-dilutive: September 30, 2017 2016 Options to purchase Common Stock 4,257,031 6,051,186 Warrants to purchase Common Stock 8,972,503 4,546,939 Restricted Stock Units 1,277,302 392,000 Series A Convertible Preferred Stock 63,125 63,125 14,569,961 11,053,250

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Schedule of the Company’s Assets and Liabilities that are Measured and Recognized at Fair Value on a Recurring Basis Classified Under the Appropriate Level of the Fair Value Hierarchy	The following table presents the Company’s assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of September 30, 2017 and December 31, 2016 : Fair Value Measurements at Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets: Money market fund (1) $ 6,510,214 $ — $ — $ 6,510,214 Total Assets $ 6,510,214 $ — $ — $ 6,510,214 Liabilities: Derivative financial instruments — warrants $ — $ — $ 2,037,712 $ 2,037,712 Total Liabilities $ — $ — 2,037,712 $ 2,037,712 Fair Value Measurements at Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets: Money market fund (1) $ 12,095,620 $ — $ — $ 12,095,620 Corporate debt securities (2) — 14,160,686 — 14,160,686 Commercial paper (3) — 2,393,948 — 2,393,948 U.S. treasury securities (2) — 8,621,892 — 8,621,892 Total Assets $ 12,095,620 $ 25,176,526 $ — $ 37,272,146 Liabilities: Derivative financial instruments — warrants $ — $ — $ 834,940 $ 834,940 Total Liabilities $ — $ — $ 834,940 $ 834,940 (1) Included as a component of cash and cash equivalents on the accompanying condensed consolidated balance sheets. (2) Included in short-term investments on the accompanying condensed consolidated balance sheets. (3) $0 and $1,198,504 of commercial paper was included as a component of cash and cash equivalents at September 30, 2017 and December 31, 2016 , respectively, and the remaining amount was included in short-term investments on the accompanying consolidated balance sheets.
Schedule of Changes in the Fair Value of the Company’s Level 3 Liabilities	The following table sets forth a summary of changes in the fair value of the Company’s Level 3 liabilities for the nine months ended September 30, 2017 : Description Balance at Issuance of Derivative Financial Instruments Realized Gain Balance at Derivative financial instruments — warrants $ 834,940 3,215,519 $ (2,012,747 ) $ 2,037,712

Short-Term Investments (Tables)

Short-Term Investments (Tables)	9 Months Ended
	Sep. 30, 2017
Investments, Debt and Equity Securities [Abstract]
Available-for-sale Securities	The following table sets forth the composition of short-term investments as of December 31, 2016 . December 31, 2016 Unrealized Maturity in Years Cost Gains Losses Fair Value Corporate debt securities Less than 1 year $ 14,165,915 $ 44 $ (5,273 ) $ 14,160,686 Commercial paper Less than 1 year 1,195,444 — — 1,195,444 U.S. treasury securities Less than 1 year 8,625,728 330 (4,166 ) 8,621,892 Total Investment $ 23,987,087 $ 374 $ (9,439 ) $ 23,978,022

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2017
Property, Plant and Equipment [Abstract]
Schedule of Components of Property and Equipment	Property and equipment consist of the following: As of September 30, As of December 31, Furniture and office equipment $ 1,076,709 $ 1,144,741 Leasehold improvements 1,994,514 1,994,514 Laboratory equipment 2,584,363 2,449,645 5,655,586 5,588,900 Less—accumulated depreciation and amortization (2,528,617 ) (1,761,985 ) Property and equipment, net $ 3,126,969 $ 3,826,915

Derivative Financial Instrume24

Derivative Financial Instruments - Warrants (Tables) - Black Scholes Option Pricing Method	9 Months Ended
	Sep. 30, 2017
Derivative financial instruments
Schedule of Assumptions Used to Determine the Fair Value of the Warrants	The range of assumptions used to determine the fair value of the warrants valued using the Black-Scholes option pricing model during the periods indicated was: Nine Months Ended September 30, 2017 2016 Estimated fair value of Trovagene common stock 0.73-1.26 4.49-4.65 Expected warrant term 1.3-5.5 years 2.3-2.8 years Risk-free interest rate 1.27-1.95% 0.71-0.87% Expected volatility 86-109% 82-89% Dividend yield 0 % 0 %
Schedule of Components of Changes in the Company’s Derivative Financial Instruments Liability Balance	The following table sets forth the components of changes in the Company’s derivative financial instruments — warrants liability balance, valued using the Black-Scholes option pricing method, for the periods indicated. Date Description Number of Warrants Derivative Instrument Liability December 31, 2016 Balance of derivative financial instruments — warrants liability 967,295 $ 834,940 Issuance of derivative financial instruments 4,643,626 3,215,519 Change in fair value of derivative financial instruments — warrants during the period recognized as a gain in the condensed consolidated statements of operations — (2,012,747 ) September 30, 2017 Balance of derivative financial instruments — warrants liability 5,610,921 $ 2,037,712

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2017
Stockholders' Equity Note [Abstract]
Schedule of Stock-Based Compensation Expense	Stock-based compensation expense related to Trovagene equity awards have been recognized in operating results as follow: Three Months Ended Nine Months Ended 2017 2016 2017 2016 Included in research and development expense $ 219,480 $ 872,792 $ 798,143 $ 1,862,069 Included in cost of revenue 15,633 42,639 56,998 99,164 Included in selling and marketing expense 118,434 476,865 550,317 1,493,744 Included in general and administrative expense 1,067,633 437,075 1,837,128 2,487,415 Benefit from restructuring — — (125,222 ) — Total stock-based compensation expense $ 1,421,180 $ 1,829,371 $ 3,117,364 $ 5,942,392
Schedule of Assumptions to Estimate Fair Value of Stock Option Awards	The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions during the following periods indicated: Nine Months Ended 2017 2016 Risk-free interest rate 1.82 % 1.48 % Dividend yield 0 % 0 % Expected volatility 87 % 103 % Expected term 5.2 years 5.5 years
Summary of Stock Option Activity and of Changes in Stock Options Outstanding	A summary of stock option activity and changes in stock options outstanding is presented below: Total Options Weighted-Average Exercise Price Per Share Intrinsic Value Balance outstanding, December 31, 2016 5,528,628 $ 5.49 $ — Granted 823,106 $ 0.84 Canceled / Forfeited (2,077,246 ) $ 6.24 Expired (17,457 ) $ 4.74 Balance outstanding, September 30, 2017 4,257,031 $ 4.23 $ 381 Exercisable at September 30, 2017 2,492,242 $ 4.79 $ —
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity	A summary of the RSU activity is presented below: Number of Shares Weighted-Average Grant Date Fair Value Per Share Intrinsic Value Non-vested RSU outstanding, December 31, 2016 272,000 $ 3.99 $ 571,200 Granted 2,249,242 $ 1.59 Vested (369,487 ) $ 3.48 $ 645,775 Forfeited (874,453 ) $ 1.75 Non-vested RSU outstanding, September 30, 2017 1,277,302 $ 1.44 $ 932,430
Summary of Warrant Activity and Changes in Warrants Outstanding	A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications is presented below: Total Warrants Weighted-Average Exercise Price Per Share Weighted-Average Remaining Contractual Term Balance outstanding, December 31, 2016 5,505,901 $ 3.83 1.6 Granted 4,643,626 $ 1.41 Expired (1,177,024 ) $ 5.32 Balance outstanding, September 30, 2017 8,972,503 $ 2.38 3.3

Organization and Basis of Pre26

Organization and Basis of Presentation (Details) $ in Millions	Oct. 25, 2017USD ($)
Subsequent Event [Member]
Subsequent Event [Line Items]
Aggregate initial offering price	$ 17.5

Summary of Significant Accoun27

Summary of Significant Accounting Policies - Warrants (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Derivative financial instruments
Derivative financial instruments—warrants	$ 2,037,712	$ 834,940
Warrants [Member] | Black Scholes Option Pricing Method
Derivative financial instruments
Derivative financial instruments—warrants	$ 2,037,712	$ 834,940

Summary of Significant Accoun28

Summary of Significant Accounting Policies - Net Loss Per Share (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Numerator:
Numerator: Net loss attributable to common shareholders	$ (4,298,026)	$ (10,197,332)	$ (22,355,494)	$ (30,674,248)
Adjustment for gain from change in fair value of derivative financial instruments—warrants	0	0	0	(533,750)
Net loss used for diluted loss per share	$ (4,298,026)	$ (10,197,332)	$ (22,355,494)	$ (31,207,998)
Denominator for basic and diluted net loss per share:
Weighted-average shares used to compute basic loss per share	36,465,672	30,339,774	32,826,306	30,018,841
Adjustments to reflect assumed exercise of warrants	0	0	0	117,731
Weighted-average shares used to compute diluted net loss per share	36,465,672	30,339,774	32,826,306	30,136,572
Net loss per share attributable to common stockholders:
Net loss per common share - basic (in USD per share)	$ (0.12)	$ (0.34)	$ (0.68)	$ (1.02)
Net loss per common share - diluted (in USD per share)	$ (0.12)	$ (0.34)	$ (0.68)	$ (1.04)

Summary of Significant Accoun29

Summary of Significant Accounting Policies - Antidilutive Securities (Details) - shares	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Net Loss Per Share
Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)	14,569,961	11,053,250
Stock Option
Net Loss Per Share
Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)	4,257,031	6,051,186
Warrants [Member]
Net Loss Per Share
Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)	8,972,503	4,546,939
Restricted Stock Units (RSUs) [Member]
Net Loss Per Share
Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)	1,277,302	392,000
Series A Convertible Preferred Stock
Net Loss Per Share
Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)	63,125	63,125

Summary of Significant Accoun30

Summary of Significant Accounting Policies - Short-Term Investments (Details) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Accounting Policies [Abstract]
Net realized loss on short-term investments	$ 6,400	$ 0

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value of Assets and Liabilities (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Liabilities:
Derivative financial instruments—warrants	$ 2,037,712	$ 834,940
Estimate of Fair Value Measurement [Member]
Assets:
Available-for-sale Securities		23,978,022
Estimate of Fair Value Measurement [Member] | Recurring basis
Assets:
Money market fund	6,510,214	12,095,620
Total Assets	6,510,214	37,272,146
Liabilities:
Derivative financial instruments—warrants	2,037,712	834,940
Total Liabilities	2,037,712	834,940
Estimate of Fair Value Measurement [Member] | Recurring basis | Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1)
Assets:
Money market fund	6,510,214	12,095,620
Total Assets	6,510,214	12,095,620
Liabilities:
Derivative financial instruments—warrants	0	0
Total Liabilities	0	0
Estimate of Fair Value Measurement [Member] | Recurring basis | Significant Other Observable Inputs (Level 2)
Assets:
Money market fund	0	0
Total Assets	0	25,176,526
Liabilities:
Derivative financial instruments—warrants	0	0
Total Liabilities	0	0
Estimate of Fair Value Measurement [Member] | Recurring basis | Significant Unobservable Inputs (Level 3)
Assets:
Money market fund	0	0
Total Assets	0	0
Liabilities:
Derivative financial instruments—warrants	2,037,712	834,940
Total Liabilities	2,037,712	834,940
Estimate of Fair Value Measurement [Member] | Corporate Debt Securities [Member]
Assets:
Available-for-sale Securities		14,160,686
Estimate of Fair Value Measurement [Member] | Corporate Debt Securities [Member] | Recurring basis
Assets:
Available-for-sale Securities		14,160,686
Estimate of Fair Value Measurement [Member] | Corporate Debt Securities [Member] | Recurring basis | Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1)
Assets:
Available-for-sale Securities		0
Estimate of Fair Value Measurement [Member] | Corporate Debt Securities [Member] | Recurring basis | Significant Other Observable Inputs (Level 2)
Assets:
Available-for-sale Securities		14,160,686
Estimate of Fair Value Measurement [Member] | Corporate Debt Securities [Member] | Recurring basis | Significant Unobservable Inputs (Level 3)
Assets:
Available-for-sale Securities		0
Estimate of Fair Value Measurement [Member] | Commercial Paper
Assets:
Available-for-sale Securities		1,195,444
Estimate of Fair Value Measurement [Member] | Commercial Paper | Recurring basis
Assets:
Available-for-sale Securities		2,393,948
Estimate of Fair Value Measurement [Member] | Commercial Paper | Recurring basis | Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1)
Assets:
Available-for-sale Securities		0
Estimate of Fair Value Measurement [Member] | Commercial Paper | Recurring basis | Significant Other Observable Inputs (Level 2)
Assets:
Available-for-sale Securities		2,393,948
Estimate of Fair Value Measurement [Member] | Commercial Paper | Recurring basis | Significant Unobservable Inputs (Level 3)
Assets:
Available-for-sale Securities		0
Estimate of Fair Value Measurement [Member] | US Treasury Securities [Member]
Assets:
Available-for-sale Securities		8,621,892
Estimate of Fair Value Measurement [Member] | US Treasury Securities [Member] | Recurring basis
Assets:
Available-for-sale Securities		8,621,892
Estimate of Fair Value Measurement [Member] | US Treasury Securities [Member] | Recurring basis | Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1)
Assets:
Available-for-sale Securities		0
Estimate of Fair Value Measurement [Member] | US Treasury Securities [Member] | Recurring basis | Significant Other Observable Inputs (Level 2)
Assets:
Available-for-sale Securities		8,621,892
Estimate of Fair Value Measurement [Member] | US Treasury Securities [Member] | Recurring basis | Significant Unobservable Inputs (Level 3)
Assets:
Available-for-sale Securities		0
Cash and Cash Equivalents [Member] | Commercial Paper | Recurring basis | Significant Other Observable Inputs (Level 2)
Assets:
Available-for-sale Securities	$ 0	$ 1,198,504

Fair Value Measurements - Chang

Fair Value Measurements - Changes in Fair Value of Level 3 Liabilities (Details) - Warrants [Member]	9 Months Ended
	Sep. 30, 2017USD ($)
Reconciliation of the beginning and ending balances
Balance at December 31, 2016	$ 834,940
Issuance of Derivative Financial Instruments	3,215,519
Unrealized Gain	(2,012,747)
Balance at September 30, 2017	$ 2,037,712

Short-Term Investments (Details

Short-Term Investments (Details)	Dec. 31, 2016USD ($)
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, amortized cost	$ 23,987,087
Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax	374
Corporate debt securities, unrealized loss	(9,439)
US Treasury Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	330
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	(4,166)
Corporate debt securities, cost	8,625,728
Commercial Paper
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	0
Corporate debt securities, cost	1,195,444
Corporate Debt Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	44
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	(5,273)
Corporate debt securities, cost	14,165,915
Estimate of Fair Value Measurement [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities	23,978,022
Estimate of Fair Value Measurement [Member] | US Treasury Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities	8,621,892
Estimate of Fair Value Measurement [Member] | Commercial Paper
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities	1,195,444
Estimate of Fair Value Measurement [Member] | Corporate Debt Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities	$ 14,160,686

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Property, equipment and depreciation and amortization
Property and equipment, gross	$ 5,655,586	$ 5,588,900
Less—accumulated depreciation and amortization	(2,528,617)	(1,761,985)
Property and equipment, net	3,126,969	3,826,915
Furniture and office equipment
Property, equipment and depreciation and amortization
Property and equipment, gross	1,076,709	1,144,741
Leasehold improvements
Property, equipment and depreciation and amortization
Property and equipment, gross	1,994,514	1,994,514
Laboratory equipment
Property, equipment and depreciation and amortization
Property and equipment, gross	$ 2,584,363	$ 2,449,645

Debt - Equipment Line of Credit

Debt - Equipment Line of Credit (Details) - Line of Credit [Member] - USD ($)	1 Months Ended	9 Months Ended
	Nov. 30, 2015	Sep. 30, 2017
Line of Credit Facility [Line Items]
Line of credit borrowing capacity (up to)	$ 2,000,000
Interest rate at end of period		5.50%
Final payment of total amounts borrowed, percentage	7.00%
Line of credit balance		$ 1,488,041
Interest expenses recorded		$ 209,082
Prime Rate [Member]
Line of Credit Facility [Line Items]
Interest above base rate	1.25%

Debt - Loan and Security Agreem

Debt - Loan and Security Agreement (Details) - USD ($)	Jun. 06, 2017	Jul. 20, 2016	Jun. 30, 2017	Nov. 30, 2015	Sep. 30, 2017	Jun. 30, 2014
Line of Credit [Member]
Debt Instrument [Line Items]
Interest expenses recorded					$ 209,082
Line of Credit [Member] | Prime Rate [Member]
Debt Instrument [Line Items]
Interest above base rate				1.25%
Secured Debt [Member]
Debt Instrument [Line Items]
Face value of term loan						$ 15,000,000
Payment for debt extinguishment	$ 16,668,583
Prepayment fee			$ 450,000
Debt discount			400,562
Unamortized portion of final fee upon repayment			$ 738,196
Interest expenses recorded					$ 801,173
Secured Debt [Member] | Line of Credit [Member] | Minimum [Member]
Debt Instrument [Line Items]
Debt instrument stated rate		7.25%
Secured Debt [Member] | Line of Credit [Member] | Prime Rate [Member]
Debt Instrument [Line Items]
Interest above base rate		3.75%

Derivative Financial Instrume37

Derivative Financial Instruments - Warrants (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Changes in the Company's derivative financial instruments liability balance
Balance of warrants outstanding at the beginning of the period (in shares)			5,505,901
Issuance of derivative financial instruments (in shares)			4,643,626
Balance of warrants outstanding at the end of the period (in shares)	8,972,503		8,972,503
Balance of derivative financial instruments liability at the beginning of the period			$ 834,940
Issuance of derivative financial instruments			3,215,519
Change in fair value of warrants during the period recognized as a gain in the condensed consolidated statement of operations	$ (1,528,669)	$ (88,208)	(2,012,747)	$ (674,834)
Balance of derivative financial instruments liability at the end of the period	$ 2,037,712		$ 2,037,712
Warrants [Member] | Black Scholes Option Pricing Method
Range of assumptions used to determine the fair value of warrants
Dividend yield (as a percent)			0.00%	0.00%
Changes in the Company's derivative financial instruments liability balance
Balance of warrants outstanding at the beginning of the period (in shares)			967,295
Issuance of derivative financial instruments (in shares)			4,643,626
Balance of warrants outstanding at the end of the period (in shares)	5,610,921		5,610,921
Balance of derivative financial instruments liability at the beginning of the period			$ 834,940
Balance of derivative financial instruments liability at the end of the period	$ 2,037,712		$ 2,037,712
Warrants [Member] | Black Scholes Option Pricing Method | Minimum [Member]
Range of assumptions used to determine the fair value of warrants
Estimated fair value of Trovagene common stock (in dollars per share)			$ 0.73	$ 4.49
Expected warrant term			1 year 3 months	2 years 3 months
Risk-free interest rate			1.27%	0.71%
Expected volatility (as a percent)			86.00%	82.00%
Warrants [Member] | Black Scholes Option Pricing Method | Maximum [Member]
Range of assumptions used to determine the fair value of warrants
Estimated fair value of Trovagene common stock (in dollars per share)			$ 1.26	$ 4.65
Expected warrant term			5 years 6 months	2 years 9 months 18 days
Risk-free interest rate			1.95%	0.87%
Expected volatility (as a percent)			109.00%	89.00%

Stockholders' Equity - Common S

Stockholders' Equity - Common Stock (Details) - USD ($)	Jul. 19, 2017	Sep. 30, 2017	Sep. 30, 2016
Class of Stock [Line Items]
Warrants granted (in shares)		4,643,626
Proceeds from sales of common stock, net of expenses		$ 6,634,803	$ 2,293,857
Restricted stock units issued during period (in shares)		369,487
Restricted stock, shares issued during period (in shares)		745,392
Common Stock [Member]
Class of Stock [Line Items]
Shares of common stock issued (in shares)		7,408,460
Registered Direct Offering [Member]
Class of Stock [Line Items]
Proceeds from sales of common stock, net of expenses		$ 7,100,000
Cantor Fitzgerald And Co [Member] | Public Offering And Controlled Equity Offering | Common Stock [Member]
Class of Stock [Line Items]
Shares of common stock issued (in shares)		102,081
Common stock, price per share (in dollars per share)		$ 1.08
Proceeds from sales of common stock, net of expenses		$ 100,000
Private Placement [Member] | Warrants [Member]
Class of Stock [Line Items]
Warrants granted (in shares)		4,643,626
Registered Direct Offering [Member] | Common Stock [Member]
Class of Stock [Line Items]
Shares of common stock issued (in shares)	6,191,500

Stockholders' Equity - Stock-ba

Stockholders' Equity - Stock-based Compensation Expense (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Stock-based compensation expense
Total stock based compensation expense	$ 1,421,180	$ 1,829,371	$ 3,117,364	$ 5,942,392
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value			3,378,243	5,416,168
Research and Development Expense
Stock-based compensation expense
Total stock based compensation expense	219,480	872,792	798,143	1,862,069
Cost of Revenue
Stock-based compensation expense
Total stock based compensation expense	15,633	42,639	56,998	99,164
Selling and Marketing Expense
Stock-based compensation expense
Total stock based compensation expense	118,434	476,865	550,317	1,493,744
General and Administrative Expense
Stock-based compensation expense
Total stock based compensation expense	1,067,633	437,075	1,837,128	2,487,415
Restructuring Charges [Member]
Stock-based compensation expense
Total stock based compensation expense	0	0	(125,222)	0
Stock Option
Stock-based compensation expense
Unrecognized compensation cost	$ 3,271,046	$ 10,416,565	$ 3,271,046	$ 10,416,565
Weighted-average remaining vesting period for recognition			2 years 2 months 23 days	2 years 11 months 19 days
Options outstanding, weighted average contractual life			7 years 2 months 19 days

Stockholders' Equity - Stock Op

Stockholders' Equity - Stock Option Activity (Details) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Jun. 13, 2017	Jun. 12, 2017	Dec. 31, 2016
Stock Option
Weighted-average assumptions
Risk-free interest rate	1.82%	1.48%
Dividend yield (as a percent)	0.00%	0.00%
Expected volatility (as a percent)	87.00%	103.00%
Expected term	5 years 2 months	5 years 6 months
Unrecognized compensation cost
Unrecognized compensation cost	$ 3,271,046	$ 10,416,565
Weighted-average remaining vesting period for recognition	2 years 2 months 23 days	2 years 11 months 19 days
Options outstanding, weighted average contractual life	7 years 2 months 19 days
Number of Options
Balance outstanding at the beginning of the period (in shares)	5,528,628
Granted (in shares)	823,106
Cancelled / Forfeited (in shares)	(2,077,246)
Expired (in shares)	(17,457)
Balance outstanding at the end of the period (in shares)	4,257,031
Vested and exercisable at the end of the period (in shares)	2,492,242
Weighted Average Exercise Price Per Share
Balance outstanding at the beginning of the period (in USD per share)	$ 5.49
Granted (in USD per share)	0.84
Canceled / Forfeited (in USD per share)	6.24
Expired (in USD per share)	4.74
Balance outstanding at the end of the period (in USD per share)	4.23
Vested and exercisable at the end of the period (in USD per share)	$ 4.79
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures
Options outstanding, intrinsic value	$ 381				$ 0
Vested and exercisable at the end of the period, intrinsic value	$ 0
2014 EIP
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures
Authorized shares under the plan (in shares)			9,500,000	7,500,000
Number of remaining shares available for issuance (in shares)	3,670,232

Stockholders' Equity - Restrict

Stockholders' Equity - Restricted Stock Units (Details) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Weighted-Average Grant Date Fair Value Per Share
Equity instruments other than options, aggregate intrinsic value, vested	$ 645,775
Restricted Stock Units (RSUs) [Member]
Number of Shares
Non-vested at beginning of period (in shares)	272,000
Granted (in shares)	2,249,242
Vested (in shares)	(369,487)
Forfeited (in shares)	(874,453)
Non-vested at end of period (in shares)	1,277,302
Weighted-Average Grant Date Fair Value Per Share
Nonvested, weighted average grant date fair value at end of period (in USD per share)	$ 3.99
Granted, weighted average grant date fair value (in USD per share)	1.59	$ 4.06
Vested, weighted average grant date fair value (in USD per share)	3.48
Forfeited (in USD per share)	1.75
Nonvested, weighted average grant date fair value at end of period (in USD per share)	$ 1.44
Equity instruments other than options, aggregate intrinsic value, nonvested	$ 932,430		$ 571,200
Share-based compensation cost not yet recognized	$ 1,011,494
Weighted-average remaining vesting period for recognition	2 years 5 months 16 days
Equity instruments other than options, vested in period, fair value	$ 1,285,578

Stockholders' Equity - Restri42

Stockholders' Equity - Restricted Stock Awards (Details) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock, shares issued during period (in shares)	745,392
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity instruments other than options, vested in period, fair value	$ 1,285,578
Granted, weighted average grant date fair value (in USD per share)	$ 1.59	$ 4.06
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity instruments other than options, vested in period, fair value	$ 596,314
Granted, weighted average grant date fair value (in USD per share)	$ 0.80

Stockholders' Equity - Warrants

Stockholders' Equity - Warrants (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Number of Warrants
Balance of warrants outstanding at the beginning of the period (in shares)	5,505,901
Granted (in shares)	4,643,626
Exercised (in shares)	(1,177,024)
Balance of warrants outstanding at the end of the period (in shares)	8,972,503	5,505,901
Weighted Average Exercise Price Per Share
Weighted average exercise price of warrants at the beginning of the period (in USD per share)	$ 3.83
Granted (in USD per share)	1.41
Exercised (in USD per share)	5.32
Weighted average exercise price of warrants at the end of the period (in USD per share)	$ 2.38	$ 3.83
Term
Weighted-Average Remaining Contractual Term	3 years 3 months 2 days	1 year 7 months 6 days

Commitments and Contingencies (

Commitments and Contingencies (Details)	1 Months Ended	9 Months Ended
	Nov. 30, 2015USD ($)ft²	Sep. 30, 2017USD ($)ft²
Commitments and Contingencies Disclosure [Abstract]
Area under lease (in square feet) | ft²	2,300	26,100
Monthly rental rate | $	$ 3,100	$ 68,000

Commitments and Contingencies -

Commitments and Contingencies - Research and Development Agreements (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2017USD ($)
Research and Development Arrangement | Research and Development Expense
Other Commitments [Line Items]
Research and Development Expense	$ 291
Norviano [Member]
Other Commitments [Line Items]
Other Commitment	1,000
Norviano [Member] | Licensing Agreements [Member]
Other Commitments [Line Items]
Research and Development Expense	$ 2,000

Commitments and Contingencies46

Commitments and Contingencies - Litigation (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2017USD ($)
Loss Contingencies [Line Items]
Accrued net cost for litigation	$ 2,100
Former CEO and CFO [Member]
Loss Contingencies [Line Items]
Net amount paid	$ 975

Commitments and Contingencies47

Commitments and Contingencies - Public Offering and Controlled Equity Offering and Database Usage (Details) - USD ($)	Jan. 25, 2013	Sep. 30, 2017	Mar. 15, 2017
Other Commitments [Line Items]
Proceeds from public offering		$ 110,000
Public Offering And Controlled Equity Offering | Selling Agents [Member]
Other Commitments [Line Items]
Commission on gross proceeds	3.00%
Public Offering And Controlled Equity Offering | Maximum [Member]
Other Commitments [Line Items]
Aggregate initial offering price			$ 20,698,357
Public Offering And Controlled Equity Offering | Maximum [Member] | Selling Agents [Member]
Other Commitments [Line Items]
Aggregate initial offering price	$ 30,000,000

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Affiliated Entity
Related Party Transaction [Line Items]
Legal Fees	$ 763,075	$ 377,464

Restructuring Charges (Details)

Restructuring Charges (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	$ 400,000		$ 400,000
Restructuring and Related Cost, Expected Cost	2,000,000		2,000,000
Restructuring Charges	$ (46,472)	$ 0	1,669,526	$ 0
Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges			1,200,000
Impaired Long-Lived Assets [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges			$ 500,000

Subsequent Events (Details)

Subsequent Events (Details) $ in Millions	Oct. 25, 2017USD ($)
Subsequent Event [Member]
Subsequent Event [Line Items]
Aggregate initial offering price	$ 17.5